1. Inicio
  2. Publicaciones
  3. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) - Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Jonas, BA
  • Cortes, JE
  • Khaled, SK
  • Martinelli, G
  • Perl, AE
  • Ganguly, S
  • Russell, NH
  • Kramer, A
  • Dombret, H
  • Hogge, D
  • Leung, AYH
  • Mehta, P
  • Radsak, MP
  • Sica, S
  • Arunachalam, M
  • Holmes, M
  • Kobayashi, K
  • Namuyinga, R
  • Ge, NX
  • Yver, A
  • Zhang, YF
  • Levis, MJ

Grupos

Abstract

Abstract no disponible

Datos de la publicación

ISSN/ISSNe:
2152-2650, 2152-2669

Clinical Lymphoma Myeloma & Leukemia  CIG MEDIA GROUP, LP

Tipo:
Meeting Abstract
Páginas:
221-222
Factor de Impacto:
0,819 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • AML; FLT3-ITD; acute myeloid leukemia

Campos de Estudio

Compartir